Published in Mol Ther on December 14, 2010
Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol (2013) 1.01
Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines. Viruses (2013) 0.95
DNA vaccination against oncoantigens: A promise. Oncoimmunology (2012) 0.85
DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway. J Biol Chem (2013) 0.85
MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS One (2012) 0.82
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines (Basel) (2013) 0.82
Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells. Mol Ther Nucleic Acids (2016) 0.82
DNA vaccines: a simple DNA sensing matter? Hum Vaccin Immunother (2013) 0.81
Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines (2015) 0.79
NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Hum Vaccin Immunother (2013) 0.79
Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother (2012) 0.77
Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget (2016) 0.76
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75
Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism. Hum Vaccin Immunother (2012) 0.75
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Mol Ther Oncolytics (2016) 0.75
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature (2009) 13.23
Recognition of microorganisms and activation of the immune response. Nature (2007) 12.99
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell (2009) 10.11
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Type I interferons in host defense. Immunity (2006) 7.32
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med (2005) 6.59
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature (1995) 5.13
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07
The interferon response circuit: induction and suppression by pathogenic viruses. Virology (2006) 4.56
Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol (2006) 4.55
Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol (2005) 3.89
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 3.51
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Pathogen recognition in the innate immune response. Biochem J (2009) 2.64
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 2.36
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest (2007) 2.24
DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23
Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res (1999) 2.00
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J Immunol (2008) 1.66
Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol (1997) 1.60
Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther (2007) 1.52
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol (2007) 1.50
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol (2009) 1.43
NF-kappaB and its regulation on the immune system. Cell Mol Immunol (2004) 1.37
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther (2009) 1.15
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol (2009) 1.00
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res (2007) 0.98
Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol (2006) 0.97
Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol (2002) 0.95
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother (2009) 0.89
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens (2002) 2.05
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood (2014) 1.80
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol (2005) 1.64
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother (2011) 1.44
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother (2011) 1.36
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood (2011) 1.24
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res (2002) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Vaccine delivery methods using viral vectors. Mol Pharm (2007) 1.17
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther (2004) 1.13
Is survivin the potential Achilles' heel of cancer? Adv Cancer Res (2011) 1.12
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother (2002) 1.05
Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res (2004) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther (2007) 1.03
Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol (2012) 1.03
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol (2007) 1.01
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther (2005) 1.01
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One (2011) 0.99
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol (2008) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res (2006) 0.97
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer (2011) 0.97
Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol Immunother (2002) 0.97
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res (2005) 0.97
Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine (2004) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer (2010) 0.96
Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One (2012) 0.96
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (2005) 0.94
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine (2005) 0.94
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells (2013) 0.93
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res (2009) 0.93
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology (2012) 0.93
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. J Transl Med (2013) 0.92
Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. FEBS Lett (2004) 0.92
The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol (2007) 0.91
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol (2004) 0.90
Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother (2009) 0.89
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug. Infect Immun (2002) 0.89
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother (2014) 0.88
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Invest Ophthalmol Vis Sci (2007) 0.88
Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol (2008) 0.88
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res (2003) 0.86
Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol (2004) 0.85
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One (2012) 0.85
IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur J Immunol (2007) 0.85
Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res (2010) 0.85
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res (2002) 0.84
HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem (2012) 0.84
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother (2012) 0.82
Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology (2012) 0.82
Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer (2011) 0.82
HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82
Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunol Immunother (2005) 0.81
Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother (2006) 0.81
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother (2009) 0.80
Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug. J Virol (2004) 0.80
Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother (2004) 0.79
Escape mechanisms in tumor immunity: an update. J Environ Pathol Toxicol Oncol (2002) 0.79